Abstract

Regulatory T cells (Tregs) are key immune regulators that have shown promise in enhancing cardiac repair post-MI, although the mechanisms remain elusive. Here, we show that rapidly increasing Treg number in the circulation post-MI via systemic administration of exogenous Tregs improves cardiac function in male mice, by limiting cardiomyocyte death and reducing fibrosis. Mechanistically, exogenous Tregs quickly home to the infarcted heart and adopt an injury-specific transcriptome that mediates repair by modulating monocytes/macrophages. Specially, Tregs lead to a reduction in pro-inflammatory Ly6CHi CCR2+ monocytes/macrophages accompanied by a rapid shift of macrophages towards a pro-repair phenotype. Additionally, exogenous Treg-derived factors, including nidogen-1 and IL-10, along with a decrease in cardiac CD8+ T cell number, mediate the reduction of the pro-inflammatory monocyte/macrophage subset in the heart. Supporting the pivotal role of IL-10, exogenous Tregs knocked out for IL-10 lose their pro-repair capabilities. Together, this study highlights the beneficial use of a Treg-based therapeutic approach for cardiac repair with important mechanistic insights that could facilitate the development of novel immunotherapies for MI.

After myocardial infarction, excessive inflammation impairs heart repair, leading to reduced cardiac function. Here, the authors show that treatment with anti-inflammatory immune cells (regulatory T cells) improves cardiac repair by modulating the activity of a specific subset of macrophages in the heart.

Details

Title
Tregs delivered post-myocardial infarction adopt an injury-specific phenotype promoting cardiac repair via macrophages in mice
Author
Alshoubaki, Yasmin K. 1   VIAFID ORCID Logo  ; Nayer, Bhavana 1   VIAFID ORCID Logo  ; Lu, Yen-Zhen 1   VIAFID ORCID Logo  ; Salimova, Ekaterina 2 ; Lau, Sin Nee 1   VIAFID ORCID Logo  ; Tan, Jean L. 1 ; Amann-Zalcenstein, Daniela 3   VIAFID ORCID Logo  ; Hickey, Peter F. 3   VIAFID ORCID Logo  ; del Monte-Nieto, Gonzalo 4   VIAFID ORCID Logo  ; Vasanthakumar, Ajithkumar 5   VIAFID ORCID Logo  ; Martino, Mikaël M. 4   VIAFID ORCID Logo 

 Monash University, European Molecular Biology Laboratory Australia, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 Monash University, Monash Biomedical Imaging, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 The Walter and Eliza Hall Institute of Medical Research, Advanced Genomics Facility, Advanced Technology and Biology Division, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Monash University, European Molecular Biology Laboratory Australia, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Victorian Heart Hospital, Victorian Heart Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 Olivia Newton-John Cancer Research Institute, Heidelberg, Australia (GRID:grid.482637.c); La Trobe University, Bundoora, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938); University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
Pages
6480
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3087030798
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.